VBI Vaccines Inc.

Equities

VBIV

CA91822J2020

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:06:44 2024-04-19 am EDT			5-day change	1st Jan Change
0.619 ^USD	-1.70%		+6.91%	+5.55%

Apr. 16	VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 15	North American Morning Briefing : Stock Futures -2-	DJ

VBI Vaccines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 09, 2022 at 08:03 am EDT

VBI Vaccines Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.126 million compared to USD 0.301 million a year ago. Net loss was USD 21.25 million compared to USD 17.65 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.07 a year ago.

Latest news about VBI Vaccines Inc.

VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma	Apr. 03	CI
VBI Vaccines Inc. Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA- Launched eVLP Vaccine Platform	Apr. 02	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences	Feb. 14	MT
VBI Vaccines Inc. Enter into New License Agreement with Brii Biosciences	Feb. 14	CI
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI	Feb. 14	MT
VBI Vaccines Inc. and VBI Cda Enters into a Forbearance Agreement with K2 HealthVentures LLC	Jan. 23	CI
VBI Vaccines Inc. and VBI Cda Enters into a Forbearance Agreement with K2 HealthVentures LLC	Dec. 26	CI
VBI Vaccines Inc. Along with Its Subsidiary VBI Cda Provides Update on Forbearance Agreement	Dec. 12	CI
VBI Vaccines Inc. along with its subsidiary VBI Cda and the Lenders Agrees to Extend the Forbearance Period Through and Including December 12, 2023	Nov. 29	CI
VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting	Nov. 20	CI
North American Morning Briefing : Stock Futures -2-	Nov. 16	DJ
Earnings Flash (VBIV) VBI VACCINES Posts Q3 Revenue $6.6M	Nov. 14	MT
VBI Vaccines Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program	23-10-26	CI
VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901	23-09-27	CI
VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM	23-09-07	CI
Earnings Flash (VBIV) VBI VACCINES Reports Q2 Revenue $720,000	23-08-14	MT
VBI Vaccines Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ

Chart VBI Vaccines Inc.

Duration

Period

More charts

Company Profile

VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for VBI Vaccines Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6297 USD

Average target price

5 USD

Spread / Average Target

+694.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VBI VACCINES INC.	+5.55%	17.9M
IQVIA HOLDINGS INC.	-1.35%	41.35B
LONZA GROUP AG	+41.82%	40.38B
MODERNA, INC.	+3.52%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+2.03%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-23.58%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.19%	11.68B
MEDPACE HOLDINGS, INC.	+21.20%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.76%	11.15B

Other Biotechnology & Medical Research